Related coverage linked through entity extraction aliases.
May 18, 2026
Charles River forecast 2026 adjusted EPS of $10.70 to $11.20, above the $10.88 consensus. The company cited improving biotech demand and said Q1 profit will decline in the high-teens.
Mar 10, 2026
Eight drug development inputs and services companies reported mixed Q4 earnings, with revenues beating consensus estimates by 1.5% as a group. Charles River Laboratories, Medpace, Fortrea, and Repligen showed varied performance.
Mar 03, 2026
Charles River Laboratories forecasts 2026 adjusted earnings of $10.70-$11.20 per share, exceeding Wall Street expectations, as biotech demand for drug research services recovers and contract cancellations decline.
Mar 02, 2026
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
Feb 18, 2026
Charles River Laboratories forecast 2026 adjusted profit of $10.70 to $11.20 per share, above Wall Street estimates, citing improved demand for drug discovery and development services from biotech clients.
Feb 14, 2026
Charles River Laboratories is scheduled to report Q4 2025 results on Feb. 18, with analysts raising price targets while the company navigates biotech funding pressures and announces new gene therapy collaborations.
